Propharmex is a specialty CDMO dedicated to advancing complex and niche pharmaceutical products from concept to commercialization. We serve as a strategic development partner, delivering end-to-end, tailored pharmaceutical solutions that address both scientific complexity and regulatory expectations. We integrate pharmaceutical development, advanced analytical services, regulatory expertise, and clinical study insight to solve complex product and pathway challenges. Our approach is built on translating deep molecule understanding into scalable, approval-ready products. Our capabilities span a broad range of complex dosage forms, including solids, liquids, topicals, injectables, ophthalmics, and transdermal systems.

Headquartered in Canada, Propharmex operates with high business standards, transparency, and global accessibility offering partners both scientific depth and a dependable international platform.